

Isis E Fernandez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12070749/publications.pdf>

Version: 2024-02-01

29
papers

3,339
citations

430874

18
h-index

477307

29
g-index

31
all docs

31
docs citations

31
times ranked

5606
citing authors

#	ARTICLE	IF	CITATIONS
1	FK506-Binding Protein 11 Is a Novel Plasma Cell-Specific Antibody Folding Catalyst with Increased Expression in Idiopathic Pulmonary Fibrosis. <i>Cells</i> , 2022, 11, 1341.	4.1	12
2	Do Circulating Monocytes Promote and Predict IPF Progression?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 9-11.	5.6	3
3	Single-cell RNA sequencing reveals ex vivo signatures of SARS-CoV-2-reactive T cells through "reverse phenotyping"™. <i>Nature Communications</i> , 2021, 12, 4515.	12.8	23
4	CX3CR1"fractalkine axis drives kinetic changes of monocytes in fibrotic interstitial lung diseases. <i>European Respiratory Journal</i> , 2020, 55, 1900460.	6.7	15
5	Biomarkers in Interstitial Lung Diseases. <i>Respiratory Medicine</i> , 2020, , 155-165.	0.1	2
6	Proteasome activator PA200 regulates myofibroblast differentiation. <i>Scientific Reports</i> , 2019, 9, 15224.	3.3	14
7	The Notch ligand DNER regulates macrophage IFN γ release in chronic obstructive pulmonary disease. <i>EBioMedicine</i> , 2019, 43, 562-575.	6.1	16
8	An atlas of the aging lung mapped by single cell transcriptomics and deep tissue proteomics. <i>Nature Communications</i> , 2019, 10, 963.	12.8	408
9	Lung Adenocarcinoma Syndecan-2 Potentiates Cell Invasiveness. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2019, 60, 659-666.	2.9	20
10	Pharmacometabolic response to pirfenidone in pulmonary fibrosis detected by MALDI-FTICR-MSI. <i>European Respiratory Journal</i> , 2018, 52, 1702314.	6.7	26
11	Systems medicine advances in interstitial lung disease. <i>European Respiratory Review</i> , 2017, 26, 170021.	7.1	4
12	Immune Mechanisms in Pulmonary Fibrosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2016, 55, 309-322.	2.9	245
13	Peripheral blood myeloid-derived suppressor cells reflect disease status in idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2016, 48, 1171-1183.	6.7	55
14	Glutathione peroxidase 3 localizes to the epithelial lining fluid and the extracellular matrix in interstitial lung disease. <i>Scientific Reports</i> , 2016, 6, 29952.	3.3	30
15	Systematic phenotyping and correlation of biomarkers with lung function and histology in lung fibrosis. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2016, 310, L919-L927.	2.9	21
16	Pharmacokinetic and pharmacometabolomic study of pirfenidone in normal mouse tissues using high mass resolution MALDI-FTICR-mass spectrometry imaging. <i>Histochemistry and Cell Biology</i> , 2016, 145, 201-211.	1.7	43
17	Association Between Interstitial Lung Abnormalities and All-Cause Mortality. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 672.	7.4	333
18	Time- and compartment- resolved proteome profiling of the extracellular niche in lung injury and repair. <i>Molecular Systems Biology</i> , 2015, 11, 819.	7.2	211

#	ARTICLE	IF	CITATIONS
19	A comparison of visual and quantitative methods to identify interstitial lung abnormalities. BMC Pulmonary Medicine, 2015, 15, 134.	2.0	39
20	FK506-Binding Protein 10, a Potential Novel Drug Target for Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 455-467.	5.6	80
21	Regulation of 26S Proteasome Activity in Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1089-1101.	5.6	38
22	Characteristic Patterns in the Fibrotic Lung. Comparing Idiopathic Pulmonary Fibrosis with Chronic Lung Allograft Dysfunction. Annals of the American Thoracic Society, 2015, 12, S34-S41.	3.2	16
23	Validation of the 2nd Generation Proteasome Inhibitor Oprozomib for Local Therapy of Pulmonary Fibrosis. PLoS ONE, 2015, 10, e0136188.	2.5	11
24	Syndecan-2 Exerts Antifibrotic Effects by Promoting Caveolin-1-mediated Transforming Growth Factor- β 2 Receptor I Internalization and Inhibiting Transforming Growth Factor- β 1 Signaling. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 831-841.	5.6	52
25	Interstitial Lung Abnormalities and Reduced Exercise Capacity. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 756-762.	5.6	106
26	New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet, The, 2012, 380, 680-688.	13.7	370
27	Statins and Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 547-556.	5.6	133
28	The Impact of TGF- β 2 on Lung Fibrosis. Proceedings of the American Thoracic Society, 2012, 9, 111-116.	3.5	530
29	Lung Volumes and Emphysema in Smokers with Interstitial Lung Abnormalities. New England Journal of Medicine, 2011, 364, 897-906.	27.0	468